Bone News and Research

RSS

Group Health Research Institute to receive federal stimulus funds from ARRA

Group Health Research Institute, formerly Group Health Center for Health Studies, will receive more than $15 million in federal stimulus funding from ARRA, the American Recovery and Reinvestment Act of 2009.

6 Oct 2009

Forsyth receives research grants from National Institutes of Health stimulus funding

Four Forsyth scientists have received grants from the latest round of National Institutes of Health stimulus funding through the American Recovery and Reinvestment Act (ARRA) of 2009. To date, Forsyth has received 13 ARRA grants totally nearly $6.4 million. The recent round of funding includes three highly competitive 'Challenge Grants'. The NIH received 22,000 submissions in the Challenge Grant competition ― only about 500 were funded.

6 Oct 2009

FOLOTYN available for commercial sale in the United States

Allos Therapeutics, Inc. today announced that FOLOTYN (pralatrexate injection) is now available for commercial sale in the United States. The U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYN for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) on September 24, 2009. This indication is based on overall response rate.

6 Oct 2009

ALS patients' bone marrow cells capable of differentiating into nerve-supporting cells

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that bone marrow cells taken from ALS patients were capable of differentiating into nerve-supporting cells.

5 Oct 2009

Registry to help patients in need of bone marrow transplants

Nearly 70 percent of patients needing a marrow transplant do not have a matching donor in their family, leaving minorities particularly vulnerable to finding a donor who can provide a perfect match of common tissue types, according to Be the Match®, a movement that engages the public to help patients in need of bone marrow or umbilical cord blood transplants.

5 Oct 2009

Younger patients have increased risk for additional ACL surgery

Anterior cruciate ligament (ACL) injuries are one of the most common injuries to the knee. Each year thousands of patients undergo reconstructive surgery to repair these injuries. According to a new study published in the October 2009 issue of The Journal of Bone and Joint Surgery (JBJS), the number of patients undergoing ACL reconstruction is increasing substantially and women and younger patients are more likely to need subsequent knee surgery following the initial repair.

5 Oct 2009

Study examines roles of PCPs and hepatologists in post-transplant care

A recent study by researchers from the University of Colorado looked at post-transplant care to determine whether primary care physicians (PCPs) or hepatologists are better suited to manage the overall health care of patients who received a liver transplant (LT).

5 Oct 2009

6.5 percent of ACL reconstruction patients undergo second knee surgery

Patients who have their anterior cruciate ligament (ACL) reconstructed are more likely to have subsequent knee surgery if they are women or are treated by a surgeon who does a low volume of ACL reconstructions, according to a study in the October 2009 TK issue of The Journal of Bone and Joint Surgery. The study, conducted by investigators at Hospital for Special Surgery, also found that overall, 6.5% of patients undergoing ACL surgery had to undergo another knee operation within one year.

3 Oct 2009

$Hip fracture patients more likely to be evaluated for osteoporosis than wrist fracture patients$

Hip fracture patients more likely to be evaluated for osteoporosis than wrist fracture patients

A study published in the October 2009 issue of the Journal of Bone and Joint Surgery suggests a disconnect between the way wrist-fracture patients and those with a spine or hip fracture are managed and evaluated. The study, conducted in 2007 among 97 percent of the women in Korea, reviewed the incidence of fractures around the hip, spine, and wrist in female patients age 50 and older and the prescription frequencies of bone density scans for osteoporosis, along with the use of medications for its treatment.

3 Oct 2009

Study points to subtle differences between boys and girls' attitudes to multiple drugs

New research by Weill Cornell Medical College researchers looks at the specific ways parents and peers influence teenagers to smoke, drink and use marijuana in combination.

3 Oct 2009

New technique to repair damaged bones developed

Spire Healthcare's private hospital in Southampton has pioneered a new technique which uses stem cells to repair damaged bones. Orthopaedic Surgeon, Mr Douglas Dunlop carried out the procedure which may prevent thousands of people from needing hip replacement operations in the future.

3 Oct 2009

New study reports PRP treatment and its use in sports medicine

Platelet -rich plasma (PRP) is currently used as an alternative treatment method for several common orthopaedic-related sports medicine conditions.

3 Oct 2009

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.

3 Oct 2009

NK cells keep T cells in check: Study

Natural killer, or NK cells, are part of our innate immune system. A healthy body produces them to respond early during infection. They are activated and they kill cells infected with a given virus.

3 Oct 2009

DelSite's assests acquired by Nanotherapeutics

Nanotherapeutics, Inc., a privately held specialty biopharmaceutical company, announced today that it had acquired certain assets from DelSite (formerly Carrington Laboratories, Inc.) out of Chapter 7 bankruptcy proceedings in the U.S. Bankruptcy Court for the Northern District of Texas, Dallas Division.

3 Oct 2009

Five-year follow-up study reveals the efficacy of OsseoSpeed implant

The five-year follow-up study was made by Dr. Steveling and co-workers at the Department of Oral and Maxillofacial Surgery at the Heidelberg University in Germany. The conclusion is that the OsseoSpeed implant shows very good results also in compromised sites when using an early loading protocol.

3 Oct 2009

ETEX' Equivabone receives additional FDA clearance for use in posterolateral spine fusion

ETEX Corporation, an advanced biomaterials company, announced today additional FDA 510(k) cleared indications for EquivaBone®. EquivaBone was the first FDA cleared hard-setting osteoinductive material and is the only osteoinductive bone graft substitute that provides a continuous nanocrystalline calcium phosphate scaffold.

3 Oct 2009

Co-marketing partnership between Enzo Life Sciences and BioTek Instruments

Enzo Biochem, Inc. announced today a co-marketing partnership between its Enzo Life Sciences subsidiary, a world leader in non-radioactive probe technology, and BioTek Instruments, a privately held global leader in the development, manufacture and sale of microplate instrumentation for drug discovery and life science applications, involving powerful, integrated solutions for high throughput live cell analysis.

3 Oct 2009

International Society for Hip Arthroscopy to focus on new procedures for hip surgery at its inaugural meeting

Recent advances in diagnostic imaging techniques and hip arthroscopy procedures are giving physicians and surgeons better tools with which to treat hip pain. The 2009 International Society for Hip Arthroscopy meeting, hosted by Hospital for Special Surgery in New York, brings together leading surgeons from all over the world to take an in-depth look at hip arthroscopy and its potential benefits.

3 Oct 2009

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).

1 Oct 2009

Bone News and Research

Group Health Research Institute to receive federal stimulus funds from ARRA

Forsyth receives research grants from National Institutes of Health stimulus funding

FOLOTYN available for commercial sale in the United States

ALS patients' bone marrow cells capable of differentiating into nerve-supporting cells

Registry to help patients in need of bone marrow transplants

Younger patients have increased risk for additional ACL surgery

Study examines roles of PCPs and hepatologists in post-transplant care

6.5 percent of ACL reconstruction patients undergo second knee surgery

Hip fracture patients more likely to be evaluated for osteoporosis than wrist fracture patients

Study points to subtle differences between boys and girls' attitudes to multiple drugs

New technique to repair damaged bones developed

New study reports PRP treatment and its use in sports medicine

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

NK cells keep T cells in check: Study

DelSite's assests acquired by Nanotherapeutics

Five-year follow-up study reveals the efficacy of OsseoSpeed implant

ETEX' Equivabone receives additional FDA clearance for use in posterolateral spine fusion

Co-marketing partnership between Enzo Life Sciences and BioTek Instruments

International Society for Hip Arthroscopy to focus on new procedures for hip surgery at its inaugural meeting

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News